Abstract
Molecular testing of thyroid fine‐needle aspiration specimens has been developed with the primary goals of resolving the uncertainty of indeterminate cytology and avoiding the diagnostic surgeries generally recommended for these patients. A recent prospective, double‐blinded, multicenter study reported the results of the clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate fine‐needle aspiration cytology.